Ying Fei Li1, Francois Pierre Combes2, Matthias Hoch3, Sebastien Lorenzo4, Sherwin K B Sy2, Yu-Yun Ho2. 1. Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA. ying_fei.li@novartis.com. 2. Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA. 3. Novartis Institute for Biomedical Research, Basel, Switzerland. 4. Novartis Pharmaceutical Corporation, Basel, Switzerland.
Abstract
BACKGROUND: Asciminib, a first-in-class, highly potent and specific ABL/BCR-ABL1 inhibitor, has shown superior efficacy compared to bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, treated with two or more tyrosine kinase inhibitors. This study aimed to describe pharmacokinetic (PK) properties of asciminib and to identify clinically relevant covariates impacting its exposure. METHODS: A population PK (PopPK) model was developed using a two-compartment model with delayed first-order absorption and elimination. The analysis included PK data from two clinical studies (Phases 1 and 3) involving 353 patients, with total daily dose of asciminib in the range of 20-400 mg. RESULTS: The nominal total daily dose was incorporated as a structural covariate on clearance (CL), and body weight (BW) was included as a structural covariate via allometric scaling on CL and central volume. Renal function and formulation were included as statistically significant covariates on CL and absorption (ka), respectively. The simulation results revealed a modest but clinically non-significant effect of baseline BW and renal function on ka. Correlations between covariates, such as baseline demographics and disease characteristics, heavy smoking status, hepatic function, and T315I mutation status, were not statistically significant with respect to CL, and they were not incorporated in the final model. Additionally, the final model-based simulations demonstrated comparable exposure and CL for asciminib 40 mg twice daily and 80 mg once daily (an alternative regimen not studied in the Phase 3 trial), as well as similar PK properties in patients with and without the T315I mutation. CONCLUSIONS: The final PopPK model adequately characterized the PK properties of asciminib and assessed the impact of key covariates on its exposure. The model corroborates the use of the approved asciminib dose of 80 mg total daily dose as 40 mg twice daily, and supports the use of 80 mg once daily as an alternative dose regimen to facilitate patient's compliance. TRIAL REGISTRATION NUMBER [DATE OF REGISTRATION]: First-in-human (CABL001X2101, Phase 1), ClinicalTrials.gov identifier: NCT02081378 [28 February 2014]; ASCEMBL (CABL001A2301, Phase 3), ClinicalTrials.gov identifier: NCT03106779 [10 April 2017].
BACKGROUND: Asciminib, a first-in-class, highly potent and specific ABL/BCR-ABL1 inhibitor, has shown superior efficacy compared to bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, treated with two or more tyrosine kinase inhibitors. This study aimed to describe pharmacokinetic (PK) properties of asciminib and to identify clinically relevant covariates impacting its exposure. METHODS: A population PK (PopPK) model was developed using a two-compartment model with delayed first-order absorption and elimination. The analysis included PK data from two clinical studies (Phases 1 and 3) involving 353 patients, with total daily dose of asciminib in the range of 20-400 mg. RESULTS: The nominal total daily dose was incorporated as a structural covariate on clearance (CL), and body weight (BW) was included as a structural covariate via allometric scaling on CL and central volume. Renal function and formulation were included as statistically significant covariates on CL and absorption (ka), respectively. The simulation results revealed a modest but clinically non-significant effect of baseline BW and renal function on ka. Correlations between covariates, such as baseline demographics and disease characteristics, heavy smoking status, hepatic function, and T315I mutation status, were not statistically significant with respect to CL, and they were not incorporated in the final model. Additionally, the final model-based simulations demonstrated comparable exposure and CL for asciminib 40 mg twice daily and 80 mg once daily (an alternative regimen not studied in the Phase 3 trial), as well as similar PK properties in patients with and without the T315I mutation. CONCLUSIONS: The final PopPK model adequately characterized the PK properties of asciminib and assessed the impact of key covariates on its exposure. The model corroborates the use of the approved asciminib dose of 80 mg total daily dose as 40 mg twice daily, and supports the use of 80 mg once daily as an alternative dose regimen to facilitate patient's compliance. TRIAL REGISTRATION NUMBER [DATE OF REGISTRATION]: First-in-human (CABL001X2101, Phase 1), ClinicalTrials.gov identifier: NCT02081378 [28 February 2014]; ASCEMBL (CABL001A2301, Phase 3), ClinicalTrials.gov identifier: NCT03106779 [10 April 2017].
Authors: Joseph Schoepfer; Wolfgang Jahnke; Giuliano Berellini; Silvia Buonamici; Simona Cotesta; Sandra W Cowan-Jacob; Stephanie Dodd; Peter Drueckes; Doriano Fabbro; Tobias Gabriel; Jean-Marc Groell; Robert M Grotzfeld; A Quamrul Hassan; Chrystèle Henry; Varsha Iyer; Darryl Jones; Franco Lombardo; Alice Loo; Paul W Manley; Xavier Pellé; Gabriele Rummel; Bahaa Salem; Markus Warmuth; Andrew A Wylie; Thomas Zoller; Andreas L Marzinzik; Pascal Furet Journal: J Med Chem Date: 2018-09-07 Impact factor: 7.446
Authors: Jan Geissler; Giora Sharf; Felice Bombaci; Mina Daban; Jan De Jong; Tony Gavin; Jana Pelouchova; Euzebiusz Dziwinski; Joerg Hasford; Verena Sophia Hoffmann Journal: J Cancer Res Clin Oncol Date: 2017-03-13 Impact factor: 4.553
Authors: Timothy P Hughes; Michael J Mauro; Jorge E Cortes; Hironobu Minami; Delphine Rea; Daniel J DeAngelo; Massimo Breccia; Yeow-Tee Goh; Moshe Talpaz; Andreas Hochhaus; Philipp le Coutre; Oliver Ottmann; Michael C Heinrich; Juan L Steegmann; Michael W N Deininger; Jeroen J W M Janssen; Francois-Xavier Mahon; Yosuke Minami; David Yeung; David M Ross; Martin S Tallman; Jae H Park; Brian J Druker; David Hynds; Yuyan Duan; Christophe Meille; Florence Hourcade-Potelleret; K Gary Vanasse; Fabian Lang; Dong-Wook Kim Journal: N Engl J Med Date: 2019-12-12 Impact factor: 91.245
Authors: Andrew A Wylie; Joseph Schoepfer; Wolfgang Jahnke; Sandra W Cowan-Jacob; Alice Loo; Pascal Furet; Andreas L Marzinzik; Xavier Pelle; Jerry Donovan; Wenjing Zhu; Silvia Buonamici; A Quamrul Hassan; Franco Lombardo; Varsha Iyer; Michael Palmer; Giuliano Berellini; Stephanie Dodd; Sanjeev Thohan; Hans Bitter; Susan Branford; David M Ross; Timothy P Hughes; Lilli Petruzzelli; K Gary Vanasse; Markus Warmuth; Francesco Hofmann; Nicholas J Keen; William R Sellers Journal: Nature Date: 2017-03-22 Impact factor: 49.962
Authors: Mohammad Houshmand; Giorgia Simonetti; Paola Circosta; Valentina Gaidano; Alessandro Cignetti; Giovanni Martinelli; Giuseppe Saglio; Robert Peter Gale Journal: Leukemia Date: 2019-05-24 Impact factor: 11.528